All In Biotech

Drug Trial Radar · NCT05743907

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Apr 25, 2023

Primary completion

Mar 10, 2025

Study completion Mar 10, 2025

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

Conditions

  • Diabetes Mellitus

Interventions

  • DA-2811Drug

    DA-2811 Group: DA-2811 + Forxiga placebo

  • ForxigaDrug

    Forxiga Group: Forxiga + DA-2811 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c(%)Time frame: Change from baseline at 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea Bucheon St. Mary's Hospital

    Bucheon-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.